Citations

Clear

1053 citation(s) found for "Andre, F".

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
Arlt, Weibke, Decoudier, B., Lasolle, Hélène , Quinkler, M., Fragoso, Maria Candida Barisson Villares , Bourdeau, Isabelle , Baudin, Éric , Berruti, Alfredo , Faßnacht, Martin , Libé, Rossella , Lacroix, André , Kaštelan, Darko , Haak, Harm Reinout , Decoudier, B., Bancos, Irina , Canu, Letizia , Puglisi, Soraya , Berchialla, Paola , Beuschlein, Felix , Bertherat, Jérôme , Terzolo, Massimo

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 1-1

10.1200/jco.2022.40.6_suppl.001 Get It

1 Background: The ESE-ENSAT guidelines on ACC management suggest adjuvant mitotane for patients at high risk of recurrence. This indication has limited evidence base, lacking results from randomized controlled trials. No suggestion for or against adjuvant mitotane in low-risk patients was given, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in patients at low-intermediate risk of recurrence. Methods: The main inclusion criteria were: stage I-III ACC, R0 surgery, and Ki-67 ≤10%. Patients were randomly assigned 1:1 to adjuvant mitotane or observation. The primary endpoint of the study was RFS. Patients who refused randomization were eligible for the ADIUVO OBSERVATIONAL study. In this prospective, observational study, patients were managed as in ADIUVO except for randomization. A total of 91 patients were enrolled in ADIUVO, 45 in the mitotane and 46 in the observation arm. Baseline characteristics of patients were perfectly matched between the 2 arms: median age, 51 vs. 50.5 years; female, 73% vs. 67%; stage I, 20% vs. 26%; stage II, 67% vs. 63%, stage III, 13% vs. 11%; ACC secretion 44% vs. 36%; Weiss 5 vs. 5; respectively. In ADIUVO OBSERVATIONAL, 42 patients were treated with mitotane and 53 were untreated. Baseline characteristics of patients were matched between the 2 groups and with mitotane and observation groups in ADIUVO. Thus, the ADIUVO OBSERVATIONAL cohort was analyzed in parallel to deal with the lower than expected recruitment in ADIUVO. Results: In the ADIUVO study, recurrences were 8 in the MIT and 11 in the OBS arm, while deaths were 2 and 5, respectively. RFS and overall survival (OS) did not significantly differ between the 2 arms. In the OBS arm, the HR for recurrence was 1.321 (95%CI, 0.55-3.32, p = 0.54) and HR for death 2.171 (95%CI, 0.52-12.12, p = 0.29). The survival analysis in the ADIUVO OBSERVATIONAL study confirmed that of ADIUVO. Given the outcome of both studies, the NNT is 55. Conclusions: ACC patients at low-intermediate risk of recurrence after surgery are a minority; however, they show a far better prognosis than expected (5-yr RFS is 75%) and do not benefit significantly from adjuvant mitotane. The results of the ADIUVO study do not support routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This is an important step toward personalization of ACC care. Clinical trial information: NCT00777244.
Vasculitis in the setting of COVID ‐19: From the disease to the vaccine. Report of a case of cutaneous vasculitis after immunization
Criado, Paulo Ricardo , Giordani, Lucas Prezotto, Yoshimoto, Thais Akemi , Vieira, Ingrid Campos, Landman, Gilles , Pincelli, Thaís , Pincelli, Thais Prota, Pincelli, T , Criado, P R

Mayo Clinic

Dermatologic Therapy | February 10, 2022 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/dth.15367 | PMID 35141989 Get It

Multi‐institutional review of non‐hypospadiac penile urethral stricture management and outcomes
Abramowitz, David , Sam, Andre‐Philippe , Pachorek, Mark, Martins, Francisco E. , Angulo, J.C. , Simhan, Jay , Li, Eric , Policastro, Connor, Ramírez-Pérez, E. A. , Burks, Frank , Shetty, Zubin, Venkatesan, K. , Hunter, Craig, Gallegos, Maxx , Foreman, Jordan , Pariser, Joseph J. , MacDonald, Susan M. , Warner, Jonathan N. , Martins, Francisco , Warner, Jonathan, Ruel, Nora H. , Nikolavsky, Dmitriy , Kasabwala, Khushabu , Lopez, Damian

Mayo Clinic

International Journal of Urology | February 3, 2022 | Volume: 29 | Issue: 5 | Pages: 376-382

10.1111/iju.14786 | PMID 35118726 Get It

Objectives Penile urethral stricture disease not associated with hypospadias is rare, and there is a wide range of commonly used surgical repair techniques for this disease. We sought to compile a multi‐institutional database of patients who had surgical correction of strictures in the penile urethra not limited to the meatus, and who had no history of hypospadias, for analysis using the Trauma and Urologic Reconstructive Network of Surgeons length, urethral segment and etiology classification system. Methods A retrospective database from 13 institutions was compiled of patients who had undergone surgical correction of Trauma and Urologic Reconstructive Network of Surgeons length, urethral segment and etiology urethral stricture segments S2b/S2c and excluding E5, with a minimum follow‐up time of 4 months. Failure was defined as cystoscopically confirmed recurrence of a stricture measuring less than 16‐Fr. Results We analyzed 222 patients with a median age of 57 years and a follow‐up of 49 months. The overall surgical success rate was 80.2%. On multivariate analysis, the two variables identified that were predictive of surgical success were stricture length ≤2 cm as well as use of a buccal mucosa graft as compared to use of a fasciocutaneous flap, which had success rates of 83% and 52%, respectively ( P = 0.0004). No statistically significant differences were found based on incisional approach or surgical technique, nor were outcomes different based on etiology or preoperative patient demographics. Conclusions Surgical repair of penile urethral strictures of non‐hypospadiac origin have a favorable overall success rate, at 80.2%. Regardless of incisional approach or surgical technique, all operations appear to have similar outcomes other than repairs using fasciocutaneous flap, which were statistically less successful than those using buccal mucosa graft.
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes
O’Malley, Grenye , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Lum, John W. , Brown, Sue A. , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Ekhlaspour, Laya , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Eggerman, Thomas L., Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Kudva, Yogish C. , Laffel, Lori M , Pinsker, Jordan E , Lum, John , Forlenza, Gregory P , Levy, Carol J. , Kovatchev, Boris , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Alonso, G. Todd , Messer, Laurel H , Buckingham, Bruce A. , Doyle, Francis J. , Beck, Roy W. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | January 31, 2022 | Volume: 24 | Issue: 5 | Pages: 357-361

10.1089/dia.2021.0431 | PMID 35099294 Get It

Objective: To analyze insulin delivery and glycemic metrics throughout the menstrual cycle for women with type 1 diabetes using closed loop control (CLC) insulin delivery. Methods: Menstruating women using a CLC system in a clinical trial were invited to record their menstrual cycles through a cycle-tracking application. Sixteen participants provided data for this secondary analysis over three or more complete cycles. Insulin delivery and continuous glucose monitoring (CGM) data were analyzed in relation to reported cycle phases. Results: Insulin delivery and CGM metrics remained consistent during cycle phases. Intraparticipant variability of CGM metrics and weight-based insulin delivery did not change through cycle phases. Conclusions: For this sample of menstruating women with type 1 diabetes using a CLC system, insulin delivery and glycemic metrics remained stable throughout menstrual cycle phases. Additional studies in this population are needed, particularly among women who report variable glycemic control during their cycles. Trial Registration: NCT03591354.
Intra-articular celecoxib improves knee extension regardless of surgical release in a rabbit model of arthrofibrosis
Trousdale, William H., Limberg, Afton K., Reina, Nicolas, Salib, Christopher G., Thaler, Roman, Dudakovic, Amel, Berry, Daniel J., Morrey, Mark E., Sanchez-Sotelo, Joaquin, Wijnen, Andre van, Abdel, Matthew P., Berry, Daniel J. , Wijnen, André J. van , van Wijnen, Andre J , Berry, Daniel J , Trousdale, William H., Limberg, Afton K., Reina, Nicolas, Salib, Christopher G., Thaler, Roman, Dudakovic, Amel, Berry, Daniel J., Morrey, Mark E., Sanchez-Sotelo, Joaquin, Abdel, Matthew P.

Mayo Clinic

Bone & Joint Research | January 27, 2022 | Volume: 11 | Issue: 1 | Pages: 32-39

10.1302/2046-3758.111.bjr-2021-0546.r1 | PMID 35084209 Get It

Aims Outcomes of current operative treatments for arthrofibrosis after total knee arthroplasty (TKA) are not consistently positive or predictable. Pharmacological in vivo studies have focused mostly on prevention of arthrofibrosis. This study used a rabbit model to evaluate intra-articular (IA) effects of celecoxib in treating contracted knees alone, or in combination with capsular release. Methods A total of 24 rabbits underwent contracture-forming surgery with knee immobilization followed by remobilization surgery at eight weeks. At remobilization, one cohort underwent capsular release (n = 12), while the other cohort did not (n = 12). Both groups were divided into two subcohorts (n = 6 each) – one receiving IA injections of celecoxib, and the other receiving injections of vehicle solution (injections every day for two weeks after remobilization). Passive extension angle (PEA) was assessed in live rabbits at 10, 16, and 24 weeks, and disarticulated limbs were analyzed for capsular stiffness at 24 weeks. Results IA celecoxib resulted in greater mean PEA at ten weeks (69.6° (SD 4.6) vs 45.2° (SD 9.6), p = 0.004), 16 weeks (109.8° (SD 24.2) vs 60.9° (SD10.9), p = 0.004), and 24 weeks (101.0° (SD 8.0) vs 66.3° (SD 5.8), p = 0.004). Capsular stiffness was significantly reduced with IA celecoxib (2.72 Newton per cm (N·cm)/° (SD 1.04), p = 0.008), capsular release (2.41 N·cm/° (SD 0.80), p = 0.008), and capsular release combined with IA celecoxib (3.56 N·cm/° (SD 0.99), p = 0.018) relative to IA vehicle (6.09 N·cm/° (SD 1.64)). Conclusion IA injections of a celecoxib led to significant improvements in passive extension angles, with reduced capsular stiffness, when administered to rabbit knees with established experimental contracture. Celecoxib was superior to surgical release, and the combination of celecoxib and a surgical release did not provide any additional value. Cite this article: Bone Joint Res 2022;11(1):32–39.
Scaffold-Free Spheroids with Two-Dimensional Heteronano-Layers (2DHNL) Enabling Stem Cell and Osteogenic Factor Codelivery for Bone Repair
Liu, Xifeng , Gaihre, Bipin , Park, Sungjo , Elder, Benjamin D. , Lu, Lichun , Li, Linli , Lu, Lichun , Li, Yong, Terzic, André

Mayo Clinic

ACS Nano | January 24, 2022 | Volume: 16 | Issue: 2 | Pages: 2741-2755

10.1021/acsnano.1c09688 | PMID 35072461 Get It

Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.
Gallois, Claire , Meyers, Jeffrey P., Gramont, Aimery de , Sobrero, Alberto F. , Haller, Daniel G. , Shields, Anthony F. , Boukovinas, Ioannis , Sougklakos, Ioannis, Papamichail, Demetris, Shi, Qian , Iveson, Timothy , Alberts, Steven R. , Oki, Eiji , Kelly, Caroline , Labianca, Roberto , Sinicrope, Frank A. , Yoshino, Takayuki , Meyerhardt, Jeffrey A. , André, Thierry , Taı̈eb, Julien

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 11-11

10.1200/jco.2022.40.4_suppl.011 Get It

11 Background: Six months of oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) remains a standard in high-risk stage III patients. Early treatment discontinuation (ETD) could worsen the prognosis. In addition, there is current lack of data on the prognostic impact of early oxaliplatin only discontinuation (EOD). Methods: We studied the prognostic impact of ETD and EOD in patients with stage III CC who participated in 11 relevant clinical trials of the ACCENT and IDEA databases, where patients were planned to receive 6 months of adjuvant fluoropyrimidine plus oxaliplatin (FOLFOX or CAPOX). ETD was defined as discontinuation of treatment before 75% of cycles of chemotherapy. EOD was defined as discontinuation of oxaliplatin only, while continuing the fluoropyrimidine, before 75% of cycles of oxaliplatin. Association between ETD/EOD and overall survival (OS) and disease-free survival (DFS) was assessed by Cox model adjusted for prognostic factors. Results: ETD analysis included 10,444 patients (FOLFOX n = 7,033; CAPOX n = 3,411), with 20.9% of patients with ETD (17.8% with FOLFOX and 27.2% with CAPOX, p < 0.001). Out of 7,243 patients, 18.8% experienced EOD (17.4% FOLFOX versus 21.4% with CAPOX, p < 0.001). Compared to patients without ETD or EOD, patients with ETD or EOD were statistically more likely to be women, older, with higher ECOG-PS ≥ 1, and in addition for ETD, a Body Mass Index (BMI) < 18.5 kg/m2. In multivariate analyses, ETD was associated with a decrease in DFS and OS in the overall population (HR: 1.40 95%CI 1.23-1.58, p < 0.001 and HR: 1.51 95%CI 1.31-1.74, p < 0.001, respectively). The same pattern was present with FOLFOX and CAPOX regimen, and also in low-risk and high-risk groups for each regimen with the exception of the CAPOX regimen in the low-risk group for DFS and OS. By contrast, EOD was not associated with reduced DFS or OS in the overall population (HR: 1.10 95%CI 0.77-1.58, p = 0.6 and HR: 0.97 95%CI 0.62-1.52, p = 0.9, respectively), in the low-risk group (HR: 0.97 95%CI 0.56-1.66, p = 0.9 and HR: 0.97 95%CI 0.51-1.82, p = 0.9, respectively) and high-risk group (HR: 1.22 95%CI 0.74-2.02, p = 0.4 and HR: 1.05 95%CI 0.53-2.08, p = 0.9, respectively) and for all subgroups of regimen. Conclusions: In patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III CC, ETD was associated with a decrease in DFS and OS. By contrast, EOD was not significantly associated with poorer outcomes. In case of relevant neurotoxicity during a 6 months schedule, these data are not in favor of continuing oxaliplatin beyond 75% of planned cycles of adjuvant chemotherapy, and demonstrate that fluoropyrimidines remain the cornerstone of adjuvant chemotherapy in localized CC.
Complications Based on Prostate Size After Plasmakinetic Enucleation of the Prostate
Mian, Abrar , Balzano, Felicia, Pachorek, Mark, Sam, Andre‐Philippe , Warner, Jonathan N. , Balzano, Felicia L, Mian, Abrar H , Ruel, Nora H.

Mayo Clinic

Journal of Endourology | January 12, 2022 | Volume: 36 | Issue: 7 | Pages: 969-976

10.1089/end.2021.0911 | PMID 35018807 Get It

Purpose: Lower urinary tract symptoms among adult men can significantly impact quality of life. We evaluated complications based on prostate size following plasmakinetic enucleation of the prostate. Materials and Methods: Patients were grouped into the small prostate group (SPG, <75 g) and large prostate group (LPG, >75 g) based on preoperative imaging. Patient data on demographics, comorbidities, preoperative international prostate symptom score (IPSS), bother index (BI), prostate-specific antigen (PSA) if indicated, postvoid residual volume (PVR), indwelling catheter or self-catheterization status, and any prior surgical intervention were evaluated. Postoperative IPSS, BI, and PVR values were assessed at 6 weeks, 4 months, and yearly. Postoperative urge urinary incontinence (UUI), stress urinary incontinence (SUI), and pad use were assessed. Results: Between September 2015 and December 2020, 296 patients who underwent bipolar enucleation with minimum follow-up of 4 months were evaluated. Postoperative IPSS, BI, PVR, and PSA values at all time points were significantly decreased compared with preoperative values ( p < 0.05). There was no significant difference in the complications between groups. Univariable and multivariable analysis found that size <75 g was predictive of stricture formation and bladder neck contracture (BNC). UUI was more common at 6 weeks in the SPG, and SUI was more common at 6 weeks in the LPG, but no difference was noted at the 4-month and 1-year time points. Pad use was equal between the two groups at all time points. Conclusions: Plasmakinetic enucleation of the prostate provides an effective treatment option for prostates of all sizes; however, prostates <75 g have a higher rate of BNC and urethral strictures compared with those >75 g.
VP7: In Vitro Comparison of Dynamic Seeding Versus Microinjection of Mesenchymal Stem Cells for Acellular Nerve Allograft
Bedar, Meiwand , Jerez, Sofía , Pulos, Nicholas , Wijnen, André J. van , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 5, 2022 | Volume: 10 | Issue: 1S | Pages: 9-9

10.1097/01.gox.0000817708.46386.37 Get It

A retinal deep phenotypingTM platform to predict the cerebral amyloid PET status in older adults
Soucy, Jean‐Paul , Chevrefils, Claudia, Osseiran, Sam , Sylvestre, Jean‐Philippe, Beaulieu, Sylvain, Arbour, Jean Daniel, Rhéaume, Marc‐André , Villeneuve, Sylvia , Nasreddine, Ziad, Gauthier, Serge , Robillard, Alain, Chayer, Céline, Shahawy, Hossam El, Scott, Christopher J.M. , Bhan, Aparna, Gupta, Sunil M., Calvin, Kirsten, Hsu, Gregory, Lowe, Val J. , Ritter, Aaron, Lesage, Frédéric , Pascoal, Tharick Ali , Provost, Karine , Rosa-Neto, Pedro , Black, Sandra E. , Kertes, Peter J. , Martins, Ralph N. , Shah, Tejal , Chen, John J.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.054582 Get It

AbstractBackgroundAs the only optically accessible part of the central nervous system, the retina represents an intriguing opportunity for the detection of biomarkers for Alzheimer’s disease (AD). This study evaluated the performance of the Retinal Deep PhenotypingTM platform, a digital biomarker platform comprising a hyperspectral retinal camera and image analysis algorithms, for the detection of likely positron‐emission tomography (PET) amyloid status (negative or positive) in older adults. A set of phenotypic features that correlates with the cerebral amyloid status as determined by amyloid PET scan were identified and used to train a classifying algorithm.MethodHyperspectral retinal images acquired with a Mydriatic Hyperspectral Retinal Camera from 194 participants (age ≥ 50 years), including cognitively normal and cognitively impaired (mild cognitive impairment and dementia) across 5 imaging sites were processed in order to train the model. Of these 194 participants, 73 individuals (38%) were amyloid‐positive, as confirmed by unanimous readings of PET scans by a panel of 3 expert reviewers. The pre‐processed hyperspectral images were segmented into various anatomical sites, and a texture‐based approach was used to extract several thousands of spatial‐spectral features. The most relevant features for the classification task were selected using a minimum redundancy maximum relevance (MRMR) algorithm and used to train a linear support vector machine (SVM) classifier. A nested, cross‐validation technique was used to evaluate the performance of the classifier.ResultThe resulting model based on the 17 most significant features showed high performance to discriminate between amyloid positive and negative subjects with an area under the receiver operating curve (AUCROC) of 0.87 (95% CI: 0.83 – 0.92).ConclusionThe Retinal Deep PhenotypingTM platform shows promise for detecting the likely cerebral amyloid PET status in adults 50 years and older from a simple, non‐invasive retinal scan and could provide an accessible means to identify individuals with abnormal cerebral amyloid in a clinical or drug development context. This phenotyping platform provides a flexible approach that could also be used for the detection of multiple biomarkers involved in cognitive decline from the same hyperspectral images of the retina.